2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Leukemia
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Leukemia, Myelomonocytic, Juvenile
2
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Down Syndrome
1
Dendritic Cell Sarcoma, Interdigitating
1
Cardiotoxicity
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Doxorubicin
17
Echocardiography
14
Exercise
9
Cyclophosphamide
9
Trastuzumab
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
hydrocortisone hemisuccinate
×
Clear all
NCT01230983
2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3
Completed
573 enrolled